139 results on '"Vigneault E"'
Search Results
2. Biochemical Failure in Intermediate Risk Prostate Cancer: Then What? Long-Term Data from a Phase III Trial
3. Ultra-Hypo Fractionated Prostate IGRT with HDR Brachytherapy Boost as Compared to a Moderate-Hypo Fractionated Approach: Patient Reported Outcomes (PRO's) of a Phase Two Study Interim Analysis
4. Combined Risk Factors and Outcomes in High-Risk Prostate Cancer: Secondary Analysis of a Phase III Trial
5. Cardiovascular Causes of Death in Patients Treated for Localized Prostate Cancer
6. Salvage Prostate Brachytherapy in Radiorecurrent Prostate Cancer: An International Delphi Consensus Study
7. A Pilot Study of Salvage HDR Brachytherapy in Recurrent Prostate Cancer: 5 Year Toxicity and Outcomes
8. Ultra-Hypofractionated (UHF) Compared to Moderate-Hypofractionated (MHF) Prostate IGRT With HDR Brachytherapy Boost (BB): Four-Year Toxicities and Local Control
9. Primary Endpoint Analysis of a Randomized Phase III Trial of Hypofractionated vs. Conventional Post-Prostatectomy Radiotherapy: NRG Oncology GU003
10. A Randomized Phase II Trial of High Dose-Rate (HDR) and Low Dose-Rate (LDR) Brachytherapy as Monotherapy in Localized Prostate Cancer: Analysis of Initial Arms of Canadian Cancer Trials Group PR19 (NCT02960087).
11. Salvage Low Dose Rate Prostate Brachytherapy: Clinical Outcomes of a Phase II Trial for Local Recurrence after External Beam Radiotherapy (NRG/RTOG -0526)
12. Analysis of PSA Kinetics and Late Treatment Related Toxicity in a Phase 2 Randomized Pilot Study Comparing High Dose Rate Brachytherapy and Low Dose Rate Brachytherapy as Monotherapy in Localized Prostate Cancer
13. IMAGE-Guided Brachytherapy for Primary Vaginal Cancers
14. Long-Term Results of NRG Oncology/RTOG 0321 A Phase II Trial of Combined High Dose Rate Brachytherapy and External Beam Radiotherapy for Adenocarcinoma of the Prostate
15. Outcomes Based on Risk Factors in Intermediate Risk Prostate Cancer: a Secondary Analysis of a Randomized Phase III Trial
16. The Advantages of Trus-Based HDR Prostate Treatment When Compared to CT Planning
17. ULTRA-HYPO (UHF) Compared to Moderate-HYPO (MHF) Fractionated Prostate IGRT with HDR Brachytherapy BOOST: LONG TERM Toxicity, Acceptability and Efficiency of Delivery
18. Short Term Androgen Deprivation Therapy Without or With Pelvic Lymph Node Treatment Added to Prostate Bed Only Salvage Radiotherapy: The NRG Oncology/RTOG 0534 SPPORT Trial
19. A Phase II Randomized Pilot Study Comparing High-Dose Rate Brachytherapy and Low-Dose Rate Brachytherapy as Monotherapy in Localized Prostate Cancer
20. Contouring and Target Variability in Vaginal Tumors Treated with MR-Based Interstitial Brachytherapy: A Multi-institutional Contouring Study
21. Significance of Testosterone Suppression in Localized Prostate Cancer Treated with Androgen Deprivation Therapy and Radiotherapy: Data from 2 Phase 3 Trials
22. The Risk of Second Malignancies after Seed Migration in Prostate Cancer Patients Treated With I-125 Free Seeds Brachytherapy
23. A Prospective Phase 2 Trial of Transperineal Ultrasound-Guided Brachytherapy for Locally Recurrent Prostate Cancer after External Beam Radiation Therapy (NRG/RTOG0526): Initial Report of Late Toxicity Outcome
24. Does Delay From Prostate Cancer Diagnosis to Treatment With Permanent Seed Implantation Increase the Risk of Disease Recurrence in Men With Clinically Localized Prostate Cancer?
25. A Pilot Study of Salvage HDR Brachytherapy in Recurrent Prostate Cancer: Toxicity Profile and Outcomes
26. Modeling Biochemical Relapse-Free Survival in Intraoperative Planned Low-Dose-Rate Prostate Brachytherapy: A Multicenter Cohort Analysis
27. Validation of a French-Canadian Version of the Expanded Prostate Cancer Index Composite Instrument (EPIC)
28. Second Malignancies as First Cause of Death in Localized Prostate Cancer Treated With Radiation Therapy: Data from Two Phase 3 Trials
29. Prognostic Groups for p16-Positive Oropharyngeal Squamous Cell Cancer (p16-OPSCC) Treated With Chemoradiation Therapy (CRT) in NRG Oncology/RTOG 0129 and 0522
30. Validation of NRG Oncology/RTOG 0129 Risk Groups for p16-Positive and p16-Negative Oropharyngeal Squamous Cell Cancer (OPSCC)
31. Radiation Therapy With or Without Short-Term Androgen Deprivation Therapy in Intermediate-Risk Prostate Cancer: Results of a Phase 3 Trial
32. NRG Oncology/RTOG 0525 Role of Machine Learning Analytic Tools for Survival Prediction of GBM Patients Using Clinical Parameters
33. Post–Biochemical Failure Risk Stratification to Predict Survival in Prostate Cancer: A Recursive Partitioning Analysis
34. Bowel and Bladder Function of Men on a Phase 3 Randomized Study of High Versus Standard Dose of 3D-CRT/IMRT in Patients Treated for Localized Prostate Cancer
35. Sexual and Hormonal Function Recuperation After Cytoreductive Drug Therapy Prior to Prostate Permanent Seeds Brachytherapy: A Randomized Trial (Dutasteride + Bicalutamide Versus LHRH Agonists)
36. Initial Results of a Phase 3 Randomized Study of High Dose 3DCRT/IMRT versus Standard Dose 3D-CRT/IMRT in Patients Treated for Localized Prostate Cancer (RTOG 0126)
37. Stereotactic Ablative Radiation Therapy Versus Low-Dose-Rate Brachytherapy: A Propensity Matched Analysis of Canadian Data
38. Androgen Deprivation Therapy in Intermediate-Risk Prostate Cancer Patients Treated With Low-Dose-Rate Brachytherapy: A Multi-institutional Propensity Score Matched Pair Analysis
39. Comparison of Permanent Seed Implant Monotherapy With Combined EBRT Plus HDR Boost in Intermediate-Risk Prostate Cancer
40. Comparison of LDR Brachytherapy Versus External Beam Radiation Therapy for Low- And Intermediate-Risk Prostate Cancer: A Propensity-Score Matched Analysis
41. Regional Outcome in N2-N3 Patients With Head and Neck Carcinoma in Function of FDG PET/CT Results
42. A Phase 3 Trial to Test Accelerated Versus Standard Fractionation in Combination With Concurrent Cisplatin for Head and Neck Carcinomas (RTOG 0129): Long-term Report of Efficacy and Toxicity
43. The Prostate Cancer Risk Stratification (ProCaRS) Project: Recursive Partitioning Risk Stratification Analysis
44. Does Phoenix Failure Definition Apply to EBRT + HDR Brachytherapy Boost in Prostate Cancer?
45. The Long-term Experience of Permanent Seed Implant Monotherapy in Low- and Intermediate-Risk Prostate Cancer
46. Determination of PTV and ITV Margins for Pelvic Lymph Nodes Irradiation in Prostate Cancer Patients Using Multiple CBCT Imaging
47. Testosterone Suppression in Patients with Intermediate Risk Prostate Cancer Treated with External Beam Radiotherapy Alone
48. Single (15 Gy) vs. 2 Fractions (of 10Gy) HDR Prostate Brachytherapy Boost: A More Practical Approach with Less Sexual Toxicity
49. Doses/Volumes Correlation with PSA Failure and Toxicity in Prostate Cancer Treated with HDR Boost
50. Phase II Trial of Combined High Dose Rate Brachytherapy and External Beam Radiotherapy for Adenocarcinoma of the Prostate: Preliminary Results of RTOG 0321
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.